Meridian BioSciences
Needs attentionClinical-stage biotech developing an oral therapy for chronic inflammatory disease, currently in Phase II.
BiotechSeries CSwitzerlandInvested Dec 3, 2019Lead: Jerry
Next board meeting
Tue, August 25
in 4 weeks
Status rationale: A competing therapy received fast-track designation, and the Phase II timeline slipped a quarter on recruitment.Updated Jul 27, 2026
Curated news for this company will appear here
No news provider is connected and none is scheduled. Nothing is shown rather than a plausible headline, because a fabricated one about a real company is something a reader cannot check.